CN107074776A - Copanlisib及其二盐酸盐的合成 - Google Patents
Copanlisib及其二盐酸盐的合成 Download PDFInfo
- Publication number
- CN107074776A CN107074776A CN201580059995.1A CN201580059995A CN107074776A CN 107074776 A CN107074776 A CN 107074776A CN 201580059995 A CN201580059995 A CN 201580059995A CN 107074776 A CN107074776 A CN 107074776A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- optionally
- copanlisib
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14192202.1A EP3018131A1 (en) | 2014-11-07 | 2014-11-07 | Synthesis of copanlisib and its dihydrochloride salt |
EP14192202.1 | 2014-11-07 | ||
PCT/EP2015/075765 WO2016071426A1 (en) | 2014-11-07 | 2015-11-05 | Synthesis of copanlisib and its dihydrochloride salt |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107074776A true CN107074776A (zh) | 2017-08-18 |
CN107074776B CN107074776B (zh) | 2021-02-02 |
Family
ID=51866060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580059995.1A Active CN107074776B (zh) | 2014-11-07 | 2015-11-05 | Copanlisib及其二盐酸盐的合成 |
Country Status (34)
Country | Link |
---|---|
US (1) | US10035803B2 (und) |
EP (2) | EP3018131A1 (und) |
JP (1) | JP6691114B2 (und) |
KR (1) | KR102562286B1 (und) |
CN (1) | CN107074776B (und) |
AR (1) | AR102568A1 (und) |
AU (1) | AU2015341779B2 (und) |
BR (1) | BR112017009471B1 (und) |
CA (1) | CA2966796C (und) |
CL (1) | CL2017001130A1 (und) |
CO (1) | CO2017004533A2 (und) |
DK (1) | DK3215507T3 (und) |
EA (1) | EA031248B1 (und) |
ES (1) | ES2716730T3 (und) |
HR (1) | HRP20190527T8 (und) |
HU (1) | HUE042794T2 (und) |
IL (1) | IL251586B (und) |
JO (1) | JO3487B1 (und) |
LT (1) | LT3215507T (und) |
MX (1) | MX365111B (und) |
MY (1) | MY183123A (und) |
NZ (1) | NZ730843A (und) |
PE (1) | PE20170951A1 (und) |
PL (1) | PL3215507T3 (und) |
PT (1) | PT3215507T (und) |
RS (1) | RS58494B1 (und) |
SG (1) | SG11201702999XA (und) |
SI (1) | SI3215507T1 (und) |
TR (1) | TR201904346T4 (und) |
TW (1) | TWI697494B (und) |
UA (1) | UA118999C2 (und) |
UY (1) | UY36396A (und) |
WO (1) | WO2016071426A1 (und) |
ZA (1) | ZA201703866B (und) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2168583A1 (en) | 2008-09-24 | 2010-03-31 | Bayer Schering Pharma Aktiengesellschaft | Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
EA037577B1 (ru) | 2013-04-08 | 2021-04-16 | Байер Фарма Акциенгезельшафт | ПРИМЕНЕНИЕ 2-АМИНО-N-[7-МЕТОКСИ-8-(3-МОРФОЛИН-4-ИЛПРОПОКСИ)-2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИН-5-ИЛ]ПИРИМИДИН-5-КАРБОКСАМИДА ИЛИ ЕГО ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМОЙ СОЛИ ИЛИ ГИДРАТА И ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ, СОДЕРЖАЩЕЙ УКАЗАННОЕ СОЕДИНЕНИЕ, ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ НЕХОДЖКИНСКОЙ ЛИМФОМЫ (НХЛ) |
EP3018127A1 (en) * | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
KR20180013851A (ko) | 2015-03-09 | 2018-02-07 | 바이엘 파마 악티엔게젤샤프트 | 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물 |
CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
US10844066B2 (en) | 2016-03-08 | 2020-11-24 | Bayer Pharma Aktiengesellschaft | 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides |
US10925880B2 (en) | 2016-09-23 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Combination of PI3K-inhibitors |
US11185549B2 (en) | 2017-06-28 | 2021-11-30 | Bayer Consumer Care Ag | Combination of a PI3K-inhibitor with an androgen receptor antagonist |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1688582A (zh) * | 2002-09-30 | 2005-10-26 | 拜尔药品公司 | 稠合吡咯-嘧啶衍生物 |
CN101631464A (zh) * | 2006-12-05 | 2010-01-20 | 拜耳先灵医药股份有限公司 | 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 |
CN103649091A (zh) * | 2011-04-05 | 2014-03-19 | 拜耳知识产权有限责任公司 | 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1319674B1 (it) * | 2000-12-01 | 2003-10-23 | Erregierre Spa | Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico. |
TW565582B (en) * | 2001-04-13 | 2003-12-11 | Kaneka Corp | Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them |
EP1417204B1 (en) * | 2001-08-15 | 2006-01-18 | E. I. du Pont de Nemours and Company | Ortho-heterocyclic substituted aryl amides for controlling invertebrate pests |
EP2244721A4 (en) * | 2008-01-14 | 2017-01-18 | Bayer Intellectual Property GmbH | Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis |
NZ599565A (en) | 2009-11-04 | 2013-05-31 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
-
2014
- 2014-11-07 EP EP14192202.1A patent/EP3018131A1/en not_active Withdrawn
-
2015
- 2015-05-11 UA UAA201705431A patent/UA118999C2/uk unknown
- 2015-11-03 JO JOP/2015/0273A patent/JO3487B1/ar active
- 2015-11-05 EP EP15790141.4A patent/EP3215507B1/en active Active
- 2015-11-05 PL PL15790141T patent/PL3215507T3/pl unknown
- 2015-11-05 CA CA2966796A patent/CA2966796C/en active Active
- 2015-11-05 US US15/524,478 patent/US10035803B2/en active Active
- 2015-11-05 KR KR1020177011704A patent/KR102562286B1/ko active IP Right Grant
- 2015-11-05 MX MX2017005891A patent/MX365111B/es active IP Right Grant
- 2015-11-05 PE PE2017000848A patent/PE20170951A1/es unknown
- 2015-11-05 NZ NZ730843A patent/NZ730843A/en unknown
- 2015-11-05 SG SG11201702999XA patent/SG11201702999XA/en unknown
- 2015-11-05 LT LTEP15790141.4T patent/LT3215507T/lt unknown
- 2015-11-05 BR BR112017009471-1A patent/BR112017009471B1/pt active IP Right Grant
- 2015-11-05 MY MYPI2017701571A patent/MY183123A/en unknown
- 2015-11-05 TR TR2019/04346T patent/TR201904346T4/tr unknown
- 2015-11-05 EA EA201790982A patent/EA031248B1/ru not_active IP Right Cessation
- 2015-11-05 WO PCT/EP2015/075765 patent/WO2016071426A1/en active Application Filing
- 2015-11-05 SI SI201530660T patent/SI3215507T1/sl unknown
- 2015-11-05 HU HUE15790141A patent/HUE042794T2/hu unknown
- 2015-11-05 PT PT15790141T patent/PT3215507T/pt unknown
- 2015-11-05 CN CN201580059995.1A patent/CN107074776B/zh active Active
- 2015-11-05 RS RS20190398A patent/RS58494B1/sr unknown
- 2015-11-05 ES ES15790141T patent/ES2716730T3/es active Active
- 2015-11-05 JP JP2017523873A patent/JP6691114B2/ja active Active
- 2015-11-05 DK DK15790141.4T patent/DK3215507T3/en active
- 2015-11-05 AU AU2015341779A patent/AU2015341779B2/en active Active
- 2015-11-06 TW TW104136727A patent/TWI697494B/zh active
- 2015-11-06 AR ARP150103617A patent/AR102568A1/es unknown
- 2015-11-06 UY UY0001036396A patent/UY36396A/es not_active Application Discontinuation
-
2017
- 2017-04-05 IL IL251586A patent/IL251586B/en active IP Right Grant
- 2017-05-05 CL CL2017001130A patent/CL2017001130A1/es unknown
- 2017-05-05 CO CONC2017/0004533A patent/CO2017004533A2/es unknown
- 2017-06-06 ZA ZA2017/03866A patent/ZA201703866B/en unknown
-
2019
- 2019-03-18 HR HRP20190527TT patent/HRP20190527T8/hr unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1688582A (zh) * | 2002-09-30 | 2005-10-26 | 拜尔药品公司 | 稠合吡咯-嘧啶衍生物 |
CN101631464A (zh) * | 2006-12-05 | 2010-01-20 | 拜耳先灵医药股份有限公司 | 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 |
CN103649091A (zh) * | 2011-04-05 | 2014-03-19 | 拜耳知识产权有限责任公司 | 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐 |
Non-Patent Citations (1)
Title |
---|
HIROMICHI FUJIOKA,ET AL: "One-pot synthesis of imidazolines from aldehydes: detailed study about solvents and substrates", 《TETRAHEDRON》 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107074776A (zh) | Copanlisib及其二盐酸盐的合成 | |
AU2015341788B2 (en) | Synthesis of copanlisib and its dihydrochloride salt | |
KR20140098131A (ko) | 스테롤 유도체의 제조 공정 | |
JP4441176B2 (ja) | テモゾロミドおよびアナログの合成 | |
CN115215853A (zh) | 一种作为法尼醇x受体激动剂的化合物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1241883 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |